US Stem Cell Inc (OTCMKTS:USRM)
US Stem Cell UPDATE!
Shares plunged on the open by around 35% after news was released by the company that it would not pursue a Regenerative Medicine Advanced Therapy FDA designation at this time. Instead, US Stem Cell will allocate resources towards expanding their existing 12 stem cell clinics and treatment centers. Volumes are heavy!
US Stem Cell Inc (OTCMKTS:USRM) released positive quarterly earnings in early May and has now announced more positive news in the form of global recognition for the efforts of its Chief Science Officer Kristin Comella.
US Stem cell, Inc. is a promising company in the stem cell industry. They focus on regenerative medicine and cellular therapy. US Stem Cell Inc (OTCMKTS:USRM) discovers, develops, and commercializes cell-based treatments that addresses disease by repairing and/or replacing damaged cell tissue, cells, and organs. US Stem Cell Inc (OTCMKTS:USRM) has three operating divisions – US Stem Cell Training, Vetbiologics, and the US Stem Cell Clinic. These divisions monetize their efforts by developing proprietary cell therapy products and training for healthcare professionals.
In 2016, the size of the global stem cell industry was estimated to be in excess of $68.7 billion. However, the market’s growth is being restricted by the high cost of treatment compounded by a lack of reimbursement policies by insurance carriers. Also contributing to growth impairment is burdensome government regulation in response to the unethical harvesting of stem cells.
US Stem Cell Inc (OTCMKTS:USRM) stock has suffered over the past few years. In 2014 USRM shares were briefly trading over $50 but today the shares can be had for under $0.10 – ten cents. Obviously there has been a lack of execution and ability to generate profits. However it appears what they do not lack is intellectual capacity. A scientific paper regarding intramyocardial implantation, co-authored by Kristin Comella, Chief Science Officer of US Stem Cell Inc (OTCMKTS:USRM), has been recognized as one of the most influential papers of 2016 according to Altmetric.com. This is not the first time that Kristin Comella has been recognized for her contributions to stem cell science. She was also named #24 on Terrapin’s list of top 50 Global Stem Cell Influencers. She was also listed at #1 on the Academy of Regenerative Practices list of Top Ten Stem Cell Innovators. Mr. Comella also led the team that achieved the first ever FDA approval for a clinical trial for a heart product that used a combination of cell and gene therapies.
Here is a link to the paper highlighted above – https://www.ncbi.nlm.nih.gov/pubmed/27255774
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $USRM and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Marc Anderson is a pseudonym. Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.